Vatinoxan

Medetomidine/vatinoxan
	Chemical structures of medetomidine (top) and vatinoxan
Combination of
Medetomidine	alpha2-adrenoceptor agonist
Vatinoxan	alpha2-adrenoceptor antagonist
Clinical data
Trade names	Zenalpha
License data	US DailyMed: Medetomidine and vatinoxan;
Routes of; administration	Intramuscular
ATC code	None;
Legal status
Legal status	CA: ℞-only; US: ℞-only;

Medetomidine/vatinoxan, sold under the brand name Zenalpha, is a veterinary fixed dose combination medication used as a sedative and analgesic for dogs.^[1]^[2] It contains medetomidine, an alpha2-adrenoceptor agonist, as the hydrochloride; and vatinoxan, an alpha2-adrenoceptor antagonist, as the hydrochloride.^[2]^[3]

It was approved for veterinary use in the United States in May 2022,^[2] and in Canada in May 2023.^[1]

References

^ ^a ^b ^c "Notice: Multiple additions to the Prescription Drug List (PDL) [2023-06-23]". Health Canada. 23 June 2023. Retrieved 3 March 2024.
^ ^a ^b ^c ^d "Zenalpha- vatinoxan hydrochloride and medetomidine hydrochloride solution". DailyMed. 11 May 2022. Retrieved 3 March 2024.
^ "Zenalpha – Label" (PDF). Dechra Veterinary Products Inc. Government of Canada. 20 March 2023.

This veterinary medicine–related article is a stub. You can help Wikipedia by expanding it.

Zdroj:https://en.wikipedia.org?pojem=Vatinoxan
Text je dostupný za podmienok Creative Commons Attribution/Share-Alike License 3.0 Unported; prípadne za ďalších podmienok. Podrobnejšie informácie nájdete na stránke Podmienky použitia.

[CA_PDL_additions-1] "Notice: Multiple additions to the Prescription Drug List (PDL) [2023-06-23]". Health Canada. 23 June 2023. Retrieved 3 March 2024.

[Zenalpha_FDA_label-2] "Zenalpha- vatinoxan hydrochloride and medetomidine hydrochloride solution". DailyMed. 11 May 2022. Retrieved 3 March 2024.

[3] "Zenalpha – Label" (PDF). Dechra Veterinary Products Inc. Government of Canada. 20 March 2023.

[1]

[2]

[3]